{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:17:13Z","timestamp":1793819833087,"version":"4.6.1"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40265-026-02365-3","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:12:02Z","timestamp":1789186322000},"page":"1661-1691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0827-5303","authenticated-orcid":false,"given":"Charlotte","family":"Beaudart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yveline","family":"Malr\u00e9chauff\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"van Heden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8662-5172","authenticated-orcid":false,"given":"Dolores","family":"Sanchez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Scheen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Mobasheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jotheeswaran Amuthavalli","family":"Thiyagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"key":"2365_CR1","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.numecd.2020.12.030","volume":"31","author":"E Mannucci","year":"2021","unstructured":"Mannucci E, Naletto L, Vaccaro G, Silverii A, Dicembrini I, Pintaudi B, et al. Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: a network meta-analysis of randomized, active comparator-controlled trials. Nutr Metab Cardiovasc Dis. 2021;31:1027\u201334. https:\/\/doi.org\/10.1016\/j.numecd.2020.12.030.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2365_CR2","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","volume":"47","author":"B Tan","year":"2023","unstructured":"Tan B, Pan XH, Chew HSJ, Goh RSJ, Lin C, Anand VV, et al. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. Int J Obes (Lond). 2023;47:677\u201385. https:\/\/doi.org\/10.1038\/s41366-023-01321-5.","journal-title":"Int J Obes (Lond)"},{"key":"2365_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177966","volume":"1003","author":"N Zamanian","year":"2025","unstructured":"Zamanian N, Imani H, Talebi S, Rahimlou M, Khosroshahi RA, Mohammadi H. The efficacy and safety of glucagon-like peptide-1 receptor agonists in non-diabetic adults with overweight\/obesity: an umbrella review of systematic reviews and meta-analyses. Eur J Pharmacol. 2025;1003:177966. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177966.","journal-title":"Eur J Pharmacol"},{"key":"2365_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13916","volume":"26","author":"O Anyiam","year":"2025","unstructured":"Anyiam O, Ardavani A, Rashid RSA, Panesar A, Idris I. How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: a systematic review and meta-analysis. Obes Rev. 2025;26:e13916. https:\/\/doi.org\/10.1111\/obr.13916.","journal-title":"Obes Rev"},{"key":"2365_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2024.102479","volume":"89","author":"DC Chan","year":"2024","unstructured":"Chan DC, Lin YC, Tzeng HP, Yang RS, Chiang MT, Liu SH. Exendin-4, a glucagon-like peptide-1 receptor agonist, alleviates muscular dysfunction and wasting in a streptozotocin-induced diabetic mouse model compared to metformin. Tissue Cell. 2024;89:102479. https:\/\/doi.org\/10.1016\/j.tice.2024.102479.","journal-title":"Tissue Cell"},{"key":"2365_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2019.154044","volume":"103","author":"AA Gurjar","year":"2020","unstructured":"Gurjar AA, Kushwaha S, Chattopadhyay S, Das N, Pal S, China SP, et al. Long acting GLP-1 analog liraglutide ameliorates skeletal muscle atrophy in rodents. Metabolism. 2020;103:154044. https:\/\/doi.org\/10.1016\/j.metabol.2019.154044.","journal-title":"Metabolism"},{"key":"2365_CR7","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.metabol.2014.05.008","volume":"63","author":"Z Li","year":"2014","unstructured":"Li Z, Ni CL, Yao Z, Chen LM, Niu WY. Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells. Metabolism. 2014;63:1022\u201330. https:\/\/doi.org\/10.1016\/j.metabol.2014.05.008.","journal-title":"Metabolism"},{"key":"2365_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2025.108975","volume":"39","author":"Q Xu","year":"2025","unstructured":"Xu Q, Qiu X, Di H, Li Z, Liu Z, Liu K. Liraglutide improves senescence and ameliorating diabetic sarcopenia via the YAP-TAZ pathway. J Diabetes Complicat. 2025;39:108975. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.108975.","journal-title":"J Diabetes Complicat"},{"key":"2365_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2021.111472","volume":"539","author":"S Yamada","year":"2022","unstructured":"Yamada S, Ogura Y, Inoue K, Tanabe J, Sugaya T, Ohata K, et al. Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats. Mol Cell Endocrinol. 2022;539:111472. https:\/\/doi.org\/10.1016\/j.mce.2021.111472.","journal-title":"Mol Cell Endocrinol"},{"key":"2365_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101681","volume":"51","author":"AJ Scheen","year":"2025","unstructured":"Scheen AJ. GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies. Diabetes Metab. 2025;51:101681. https:\/\/doi.org\/10.1016\/j.diabet.2025.101681.","journal-title":"Diabetes Metab"},{"key":"2365_CR11","doi-asserted-by":"publisher","first-page":"369","DOI":"10.21037\/atm.2019.06.74","volume":"7","author":"L Zhang","year":"2019","unstructured":"Zhang L, Li P, Tang Z, Dou Q, Feng B. Effects of GLP-1 receptor analogue liraglutide and DPP-4 inhibitor vildagliptin on the bone metabolism in ApoE(-\/-) mice. Ann Transl Med. 2019;7:369. https:\/\/doi.org\/10.21037\/atm.2019.06.74.","journal-title":"Ann Transl Med"},{"key":"2365_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1410883","volume":"15","author":"MEA Mostafa","year":"2024","unstructured":"Mostafa MEA, Alrasheed T. Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies. Front Endocrinol (Lausanne). 2024;15:1410883. https:\/\/doi.org\/10.3389\/fendo.2024.1410883.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2365_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3843","volume":"40","author":"HJ Kim","year":"2024","unstructured":"Kim HJ, Choi SA, Gu MS, Ko SY, Kwon JH, Han JY, et al. Effects of glucagon-like peptide-1 receptor agonist on bone mineral density and bone turnover markers: a meta-analysis. Diabetes Metab Res Rev. 2024;40:e3843. https:\/\/doi.org\/10.1002\/dmrr.3843.","journal-title":"Diabetes Metab Res Rev"},{"key":"2365_CR14","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/dom.12932","volume":"19","author":"J Blundell","year":"2017","unstructured":"Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19:1242\u201351. https:\/\/doi.org\/10.1111\/dom.12932.","journal-title":"Diabetes Obes Metab"},{"key":"2365_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156113","volume":"164","author":"P Karakasis","year":"2025","unstructured":"Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2025;164:156113. https:\/\/doi.org\/10.1016\/j.metabol.2024.156113.","journal-title":"Metabolism"},{"key":"2365_CR16","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S, Udden Hemmingsson J, Hjelmesaeth J, Hoffmann Morville T, et al. Once-weekly Semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med. 2024;391:1573\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2403664.","journal-title":"N Engl J Med"},{"key":"2365_CR17","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s40265-020-01423-8","volume":"80","author":"C Beaudart","year":"2020","unstructured":"Beaudart C, Lengele L, Leclercq V, Geerinck A, Sanchez-Rodriguez D, Bruyere O, et al. Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: a systematic review and a network meta-analysis with a 6-month time horizon. Drugs. 2020;80:1947\u201359. https:\/\/doi.org\/10.1007\/s40265-020-01423-8.","journal-title":"Drugs"},{"key":"2365_CR18","volume-title":"Metabolism: clinical and experimental","author":"Y Rolland","year":"2023","unstructured":"Rolland Y, Dray C, Vellas B, Barreto PDS. Current and investigational medications for the treatment of sarcopenia. In: Metabolism: clinical and experimental. W.B. Saunders; 2023."},{"key":"2365_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"2365_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1017\/S0266462312000086","volume":"28","author":"A Morrison","year":"2012","unstructured":"Morrison A, Polisena J, Husereau D, Moulton K, Clark M, Fiander M, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care. 2012;28:138\u201344. https:\/\/doi.org\/10.1017\/S0266462312000086.","journal-title":"Int J Technol Assess Health Care"},{"key":"2365_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jclinepi.2021.04.012","volume":"137","author":"AI Dobrescu","year":"2021","unstructured":"Dobrescu AI, Nussbaumer-Streit B, Klerings I, Wagner G, Persad E, Sommer I, et al. Restricting evidence syntheses of interventions to English-language publications is a viable methodological shortcut for most medical topics: a systematic review. J Clin Epidemiol. 2021;137:209\u201317. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.04.012.","journal-title":"J Clin Epidemiol"},{"key":"2365_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"2365_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. https:\/\/doi.org\/10.1186\/1471-2288-5-13.","journal-title":"BMC Med Res Methodol"},{"key":"2365_CR24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"2365_CR25","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1111\/dom.15579","volume":"26","author":"R Golubic","year":"2024","unstructured":"Golubic R, Kennet J, Parker V, Robertson D, Luo D, Hansen L, et al. Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. Diabetes Obes Metab. 2024;26:2634\u201344. https:\/\/doi.org\/10.1111\/dom.15579.","journal-title":"Diabetes Obes Metab"},{"key":"2365_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102624","volume":"72","author":"MS Hansen","year":"2024","unstructured":"Hansen MS, Wolfel EM, Jeromdesella S, Moller JK, Ejersted C, Jorgensen NR, et al. Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial. EClinicalMedicine. 2024;72:102624. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102624.","journal-title":"EClinicalMedicine."},{"key":"2365_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/oby.24222","volume":"33","author":"RF Kushner","year":"2025","unstructured":"Kushner RF, Ryan DH, Deanfield J, Kokkinos A, Cercato C, Wilding J, et al. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring). 2025;33:452\u201362. https:\/\/doi.org\/10.1002\/oby.24222.","journal-title":"Obesity (Silver Spring)"},{"key":"2365_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s13340-024-00717-6","volume":"15","author":"Y Kondo","year":"2024","unstructured":"Kondo Y, Satoh S, Terauchi Y. Effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes: a randomized controlled study: DUET-beta study. Diabetol Int. 2024;15:474\u201382. https:\/\/doi.org\/10.1007\/s13340-024-00717-6.","journal-title":"Diabetol Int"},{"key":"2365_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035394","volume":"102","author":"OZ Akyay","year":"2023","unstructured":"Akyay OZ, Canturk Z, Selek A, Cetinarslan B, Tarkun I, Cakmak Y, et al. The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus. Medicine (Baltimore). 2023;102:e35394. https:\/\/doi.org\/10.1097\/MD.0000000000035394.","journal-title":"Medicine (Baltimore)"},{"key":"2365_CR30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/oby.23633","volume":"31","author":"KD Corbin","year":"2023","unstructured":"Corbin KD, Carnero EA, Allerton TD, Tillner J, Bock CP, Luyet PP, et al. Glucagon-like peptide-1\/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: a randomized trial. Obesity. 2023;31:350\u201362. https:\/\/doi.org\/10.1002\/oby.23633.","journal-title":"Obesity"},{"key":"2365_CR31","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2337\/dc22-1710","volume":"46","author":"T Heise","year":"2023","unstructured":"Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care. 2023;46:998\u20131004. https:\/\/doi.org\/10.2337\/dc22-1710.","journal-title":"Diabetes Care"},{"key":"2365_CR32","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamasurg.2023.2930","volume":"158","author":"J Mok","year":"2023","unstructured":"Mok J, Adeleke MO, Brown A, Magee CG, Firman C, Makahamadze C, et al. Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial. JAMA Surg. 2023;158:1003\u201311. https:\/\/doi.org\/10.1001\/jamasurg.2023.2930.","journal-title":"JAMA Surg"},{"key":"2365_CR33","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1111\/dom.15113","volume":"25","author":"HJ Silver","year":"2023","unstructured":"Silver HJ, Olson D, Mayfield D, Wright P, Nian H, Mashayekhi M, et al. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: a randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab. 2023;25:2340\u201350. https:\/\/doi.org\/10.1111\/dom.15113.","journal-title":"Diabetes Obes Metab"},{"key":"2365_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ocarto.2022.100255","volume":"4","author":"C Bartholdy","year":"2022","unstructured":"Bartholdy C, Overgaard A, Gudbergsen H, Bliddal H, Kristensen LE, Henriksen M. Changes in physical activity during a one-year weight loss trial with liraglutide vs placebo in participants with knee osteoarthritis: secondary analyses of a randomised controlled trial. Osteoarthritis Cartilage Open. 2022;4:100255. https:\/\/doi.org\/10.1016\/j.ocarto.2022.100255.","journal-title":"Osteoarthritis Cartilage Open"},{"key":"2365_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038.","journal-title":"N Engl J Med"},{"key":"2365_CR36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/dom.14568","volume":"24","author":"NJ Johansen","year":"2022","unstructured":"Johansen NJ, Dejgaard TF, Lund A, Schluntz C, Hartmann B, Holst JJ, et al. Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes. Diabetes Obes Metab. 2022;24:221\u20137. https:\/\/doi.org\/10.1111\/dom.14568.","journal-title":"Diabetes Obes Metab"},{"key":"2365_CR37","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/dom.14567","volume":"24","author":"S Schmidt","year":"2022","unstructured":"Schmidt S, Frandsen CS, Dejgaard TF, Vistisen D, Halldorsson T, Olsen SF, et al. Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes. Diabetes Obes Metab. 2022;24:212\u201320. https:\/\/doi.org\/10.1111\/dom.14567.","journal-title":"Diabetes Obes Metab"},{"key":"2365_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41366-021-01043-6","volume":"46","author":"AH Shoemaker","year":"2022","unstructured":"Shoemaker AH, Silver HJ, Buchowski M, Slaughter JC, Yanovski JA, Elfers C, et al. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist. Int J Obes (Lond). 2022;46:623\u20139. https:\/\/doi.org\/10.1038\/s41366-021-01043-6.","journal-title":"Int J Obes (Lond)"},{"key":"2365_CR39","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3361309","volume":"2021","author":"TT Cai","year":"2021","unstructured":"Cai TT, Li HQ, Jiang LL, Wang HY, Luo MH, Su XF, et al. Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study. BioMed Res Int. 2021;2021:3361309. https:\/\/doi.org\/10.1155\/2021\/3361309.","journal-title":"BioMed Res Int"},{"key":"2365_CR40","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/dom.14255","volume":"23","author":"C Gibbons","year":"2021","unstructured":"Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23:581\u20138. https:\/\/doi.org\/10.1111\/dom.14255.","journal-title":"Diabetes Obes Metab"},{"key":"2365_CR41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1093\/ajcn\/nqaa328","volume":"113","author":"H Gudbergsen","year":"2021","unstructured":"Gudbergsen H, Overgaard A, Henriksen M, Waehrens EE, Bliddal H, Christensen R, et al. Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr. 2021;113:314\u201323. https:\/\/doi.org\/10.1093\/ajcn\/nqaa328.","journal-title":"Am J Clin Nutr"},{"key":"2365_CR42","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","volume":"384","author":"JR Lundgren","year":"2021","unstructured":"Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384:1719\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2028198.","journal-title":"N Engl J Med"},{"key":"2365_CR43","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","volume":"9","author":"IJ Neeland","year":"2021","unstructured":"Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021;9:595\u2013605. https:\/\/doi.org\/10.1016\/S2213-8587(21)00179-0.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2365_CR44","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"key":"2365_CR45","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1111\/dom.14090","volume":"22","author":"H Ghanim","year":"2020","unstructured":"Ghanim H, Batra M, Green K, Abuaysheh S, Hejna J, Makdissi A, et al. Liraglutide treatment in overweight and obese patients with type 1 diabetes: a 26-week randomized controlled trial; mechanisms of weight loss. Diabetes Obes Metab. 2020;22:1742\u201352. https:\/\/doi.org\/10.1111\/dom.14090.","journal-title":"Diabetes Obes Metab"},{"key":"2365_CR46","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1210\/clinem\/dgz140","volume":"105","author":"H Kadouh","year":"2020","unstructured":"Kadouh H, Chedid V, Halawi H, Burton DD, Clark MM, Khemani D, et al. GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity. J Clin Endocrinol Metab. 2020;105:1552\u201363. https:\/\/doi.org\/10.1210\/clinem\/dgz140.","journal-title":"J Clin Endocrinol Metab"},{"key":"2365_CR47","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","volume":"63","author":"RJ McCrimmon","year":"2020","unstructured":"McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63:473\u201385. https:\/\/doi.org\/10.1007\/s00125-019-05065-8.","journal-title":"Diabetologia"},{"key":"2365_CR48","doi-asserted-by":"publisher","unstructured":"van Eyk HJ, Paiman EHM, Bizino MB, SL IJ, Kleiburg F, Boers TGW, Rappel EJ, Burakiewicz J, Kan HE, Smit JWA, et al. Liraglutide decreases energy expenditure and does not affect the fat fraction of supraclavicular brown adipose tissue in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2020;30:616\u2013624. https:\/\/doi.org\/10.1016\/j.numecd.2019.12.005","DOI":"10.1016\/j.numecd.2019.12.005"},{"key":"2365_CR49","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/oby.22726","volume":"28","author":"TA Wadden","year":"2020","unstructured":"Wadden TA, Tronieri JS, Sugimoto D, Lund MT, Auerbach P, Jensen C, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020;28:529\u201336. https:\/\/doi.org\/10.1002\/oby.22726.","journal-title":"Obesity (Silver Spring)"},{"key":"2365_CR50","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/jdi.12888","volume":"10","author":"WH Feng","year":"2019","unstructured":"Feng WH, Bi Y, Li P, Yin TT, Gao CX, Shen SM, et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial. J Diabetes Investig. 2019;10:399\u2013407. https:\/\/doi.org\/10.1111\/jdi.12888.","journal-title":"J Diabetes Investig"},{"key":"2365_CR51","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"key":"2365_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.115197","volume":"132","author":"K Hygum","year":"2020","unstructured":"Hygum K, Harslof T, Jorgensen NR, Rungby J, Pedersen SB, Langdahl BL. Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial. Bone. 2020;132:115197. https:\/\/doi.org\/10.1016\/j.bone.2019.115197.","journal-title":"Bone"},{"key":"2365_CR53","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.diabet.2018.08.010","volume":"45","author":"AM Wagner","year":"2019","unstructured":"Wagner AM, Miranda-Calderin G, Ugarte-Lopetegui MA, Marrero-Santiago H, Suarez-Castellano L, Lopez-Madrazo MJ, et al. Effect of liraglutide on physical performance in type 2 diabetes: results of a randomized, double-blind, controlled trial (LIPER2). Diabetes Metab. 2019;45:268\u201375. https:\/\/doi.org\/10.1016\/j.diabet.2018.08.010.","journal-title":"Diabetes Metab"},{"key":"2365_CR54","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/dom.13063","volume":"20","author":"MC Dube","year":"2018","unstructured":"Dube MC, D\u2019Amours M, Weisnagel SJ. Beyond glycaemic control: a cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes. Diabetes Obes Metab. 2018;20:178\u201384. https:\/\/doi.org\/10.1111\/dom.13063.","journal-title":"Diabetes Obes Metab"},{"key":"2365_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12986-018-0295-6","volume":"15","author":"TT Yin","year":"2018","unstructured":"Yin TT, Bi Y, Li P, Shen SM, Wang WM, Jiang C, et al. Effects of exenatide versus insulin glargine on body composition in overweight and obese T2DM patients: a randomized controlled trial. Nutr Metab (Lond). 2018;15:67. https:\/\/doi.org\/10.1186\/s12986-018-0295-6.","journal-title":"Nutr Metab (Lond)"},{"key":"2365_CR56","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1507\/endocrj.EJ16-0449","volume":"64","author":"R Bouchi","year":"2017","unstructured":"Bouchi R, Nakano Y, Fukuda T, Takeuchi T, Murakami M, Minami I, et al. Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Endocr J. 2017;64:269\u201381. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0449.","journal-title":"Endocr J"},{"key":"2365_CR57","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","volume":"19","author":"A Jorsal","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69\u201377. https:\/\/doi.org\/10.1002\/ejhf.657.","journal-title":"Eur J Heart Fail"},{"key":"2365_CR58","doi-asserted-by":"publisher","unstructured":"Mensberg P, Nyby S, Jorgensen PG,Storgaard H, Jensen MT, Sivertsen J, et al. Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. Diabetes Obes Metab 2017;19:172\u201380. https:\/\/doi.org\/10.1111\/dom.12797.","DOI":"10.1111\/dom.12797"},{"key":"2365_CR59","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","volume":"316","author":"KB Margulies","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500\u20138. https:\/\/doi.org\/10.1001\/jama.2016.10260.","journal-title":"JAMA"},{"key":"2365_CR60","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4158\/EP15758.OR","volume":"22","author":"MP Gilbert","year":"2016","unstructured":"Gilbert MP, Marre M, Holst JJ, Garber A, Baeres FM, Thomsen H, et al. Comparison of the long-term effects of liraglutide and glimepiride monotherapy on bone mineral density in patients with type 2 diabetes. Endocr Pract. 2016;22:406\u201311. https:\/\/doi.org\/10.4158\/EP15758.OR.","journal-title":"Endocr Pract"},{"key":"2365_CR61","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1210\/jc.2015-1176","volume":"100","author":"EW Iepsen","year":"2015","unstructured":"Iepsen EW, Lundgren JR, Hartmann B, Pedersen O, Hansen T, Jorgensen NR, et al. GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women. J Clin Endocrinol Metab. 2015;100:2909\u201317. https:\/\/doi.org\/10.1210\/jc.2015-1176.","journal-title":"J Clin Endocrinol Metab"},{"key":"2365_CR62","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/ijo.2011.158","volume":"36","author":"A Astrup","year":"2012","unstructured":"Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843\u201354. https:\/\/doi.org\/10.1038\/ijo.2011.158.","journal-title":"Int J Obes (Lond)"},{"key":"2365_CR63","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1463-1326.2010.01355.x","volume":"13","author":"MC Bunck","year":"2011","unstructured":"Bunck MC, Eliasson B, Corner A, Heine RJ, Shaginian RM, Taskinen MR, et al. Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:374\u20137. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01355.x.","journal-title":"Diabetes Obes Metab"},{"key":"2365_CR64","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.2337\/dc09-2361","volume":"33","author":"MC Bunck","year":"2010","unstructured":"Bunck MC, Diamant M, Eliasson B, Corner A, Shaginian RM, Heine RJ, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care. 2010;33:1734\u20137. https:\/\/doi.org\/10.2337\/dc09-2361.","journal-title":"Diabetes Care"},{"key":"2365_CR65","doi-asserted-by":"publisher","unstructured":"Jendle J, Nauck MA, Matthews DR, Frid A, Hermansen K, During M, Zdravkovic M, Strauss BJ, Garber AJ, Lead, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11:1163\u20131172. https:\/\/doi.org\/10.1111\/j.1463-1326.2009.01158.x","DOI":"10.1111\/j.1463-1326.2009.01158.x"},{"key":"2365_CR66","doi-asserted-by":"publisher","unstructured":"Harder H, Nielsen L, Thi TDT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients withtype 2 diabetes. Diabetes Care. 2004;27:1915-21. https:\/\/doi.org\/10.2337\/diacare.27.8.1915.","DOI":"10.2337\/diacare.27.8.1915"},{"key":"2365_CR67","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2147\/DDDT.S445415","volume":"18","author":"JE Song","year":"2024","unstructured":"Song JE, Ko HJ, Kim AS. Comparison of the efficacy of anti-obesity medications in real-world practice. Drug Des Devel Ther. 2024;18:845\u201358. https:\/\/doi.org\/10.2147\/DDDT.S445415.","journal-title":"Drug Des Devel Ther"},{"key":"2365_CR68","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s00592-024-02415-w","volume":"62","author":"Y Xiao","year":"2025","unstructured":"Xiao Y, Zhou M, Xiao W. Fracture events associated with GLP-1 receptor agonists in FDA adverse events reporting system. Acta Diabetol. 2025;62:1009\u201321. https:\/\/doi.org\/10.1007\/s00592-024-02415-w.","journal-title":"Acta Diabetol"},{"key":"2365_CR69","doi-asserted-by":"publisher","first-page":"308","DOI":"10.29271\/jcpsp.2023.03.308","volume":"33","author":"E Agcakaya","year":"2023","unstructured":"Agcakaya E, Mutlu HH, Erbakan A, Sargin M. Comparison of the impact of SGLT2-inhibitors and exenatide on body fat composition. J Coll Physicians Surg Pak. 2023;33:308\u201313. https:\/\/doi.org\/10.29271\/jcpsp.2023.03.308.","journal-title":"J Coll Physicians Surg Pak"},{"key":"2365_CR70","doi-asserted-by":"publisher","first-page":"e2335797","DOI":"10.1001\/jamanetworkopen.2023.35797","volume":"6","author":"HY Ko","year":"2023","unstructured":"Ko HY, Bea S, Jeong HE, Park S, Cho YM, Kong SH, et al. Sodium-glucose cotransporter 2 inhibitors vs incretin-based drugs and risk of fractures for type 2 diabetes. JAMA Netw Open. 2023;6:e2335797. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.35797.","journal-title":"JAMA Netw Open"},{"key":"2365_CR71","doi-asserted-by":"publisher","DOI":"10.1177\/11795514231161885","volume":"16","author":"T Osaka","year":"2023","unstructured":"Osaka T, Hamaguchi M, Fukui M. Favorable appendicular skeletal muscle mass changes in older patients with type 2 diabetes receiving GLP-1 receptor agonist and basal insulin co-therapy. Clin Med Insights Endocrinol Diabetes. 2023;16:11795514231161885. https:\/\/doi.org\/10.1177\/11795514231161885.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"2365_CR72","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.amjcard.2023.06.016","volume":"201","author":"T Patil","year":"2023","unstructured":"Patil T, Cook M, Hobson J, Kaur A, Lee A. Evaluating the safety of sodium-glucose cotransporter-2 inhibitors in a nationwide Veterans Health Administration observational cohort study. Am J Cardiol. 2023;201:281\u201393. https:\/\/doi.org\/10.1016\/j.amjcard.2023.06.016.","journal-title":"Am J Cardiol"},{"key":"2365_CR73","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1136\/ard-2023-223845","volume":"82","author":"H Zhu","year":"2023","unstructured":"Zhu H, Zhou L, Wang Q, Cai Q, Yang F, Jin H, et al. Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis. 2023;82:1218\u201326. https:\/\/doi.org\/10.1136\/ard-2023-223845.","journal-title":"Ann Rheum Dis"},{"key":"2365_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.882998","volume":"13","author":"ZK Al-Mashhadi","year":"2022","unstructured":"Al-Mashhadi ZK, Viggers R, Fuglsang-Nielsen R, Vestergaard P, Gregersen S, Starup-Linde J. The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors: a Danish nationwide cohort study. Front Endocrinol (Lausanne). 2022;13:882998. https:\/\/doi.org\/10.3389\/fendo.2022.882998.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2365_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.861422","volume":"13","author":"ZK Al-Mashhadi","year":"2022","unstructured":"Al-Mashhadi ZK, Viggers R, Starup-Linde J, Vestergaard P, Gregersen S. SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: a nationwide cohort study. Front Endocrinol (Lausanne). 2022;13:861422. https:\/\/doi.org\/10.3389\/fendo.2022.861422.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2365_CR76","doi-asserted-by":"publisher","first-page":"6813","DOI":"10.26355\/eurrev_202209_29783","volume":"26","author":"L Keskin","year":"2022","unstructured":"Keskin L, Yaprak B. Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 2022;26:6813\u201320. https:\/\/doi.org\/10.26355\/eurrev_202209_29783.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2365_CR77","doi-asserted-by":"publisher","first-page":"826","DOI":"10.2337\/dc20-1464","volume":"44","author":"E Patorno","year":"2021","unstructured":"Patorno E, Pawar A, Bessette LG, Kim DH, Dave C, Glynn RJ, et al. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care. 2021;44:826\u201335. https:\/\/doi.org\/10.2337\/dc20-1464.","journal-title":"Diabetes Care"},{"key":"2365_CR78","doi-asserted-by":"publisher","first-page":"e2130762","DOI":"10.1001\/jamanetworkopen.2021.30762","volume":"4","author":"M Zhuo","year":"2021","unstructured":"Zhuo M, Hawley CE, Paik JM, Bessette LG, Wexler DJ, Kim DH, et al. Association of sodium-glucose cotransporter-2 inhibitors with fracture risk in older adults with type 2 diabetes. JAMA Netw Open. 2021;4:e2130762. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.30762.","journal-title":"JAMA Netw Open"},{"key":"2365_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4365","volume":"363","author":"P Ueda","year":"2018","unstructured":"Ueda P, Svanstrom H, Melbye M, Eliasson B, Svensson AM, Franzen S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. https:\/\/doi.org\/10.1136\/bmj.k4365.","journal-title":"BMJ"},{"key":"2365_CR80","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00223-015-9993-5","volume":"97","author":"JH Driessen","year":"2015","unstructured":"Driessen JH, Henry RM, van Onzenoort HA, Lalmohamed A, Burden AM, Prieto-Alhambra D, et al. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis. Calcif Tissue Int. 2015;97:104\u201312. https:\/\/doi.org\/10.1007\/s00223-015-9993-5.","journal-title":"Calcif Tissue Int"},{"key":"2365_CR81","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1530\/JOE-11-0015","volume":"209","author":"B Nuche-Berenguer","year":"2011","unstructured":"Nuche-Berenguer B, Lozano D, Gutierrez-Rojas I, Moreno P, Marinoso ML, Esbrit P, et al. GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. J Endocrinol. 2011;209:203\u201310. https:\/\/doi.org\/10.1530\/JOE-11-0015.","journal-title":"J Endocrinol"},{"key":"2365_CR82","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/1785321","volume":"2024","author":"X Li","year":"2024","unstructured":"Li X, Li Y, Lei C. Effects of Glucagon-Like Peptide-1 Receptor Agonists on bone metabolism in type 2 diabetes mellitus: a systematic review and meta-analysis. Int J Endocrinol. 2024;2024:1785321. https:\/\/doi.org\/10.1155\/2024\/1785321.","journal-title":"Int J Endocrinol"},{"key":"2365_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.697442","volume":"12","author":"B Xie","year":"2021","unstructured":"Xie B, Chen S, Xu Y, Han W, Hu R, Chen M, et al. The impact of Glucagon-Like Peptide 1 Receptor Agonists on bone metabolism and its possible mechanisms in osteoporosis treatment. Front Pharmacol. 2021;12:697442. https:\/\/doi.org\/10.3389\/fphar.2021.697442.","journal-title":"Front Pharmacol"},{"key":"2365_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00098","volume":"8","author":"C Zhao","year":"2017","unstructured":"Zhao C, Liang J, Yang Y, Yu M, Qu X. The impact of Glucagon-Like Peptide-1 on bone metabolism and its possible mechanisms. Front Endocrinol (Lausanne). 2017;8:98. https:\/\/doi.org\/10.3389\/fendo.2017.00098.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2365_CR85","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.nutr.012809.104655","volume":"32","author":"SA Shapses","year":"2012","unstructured":"Shapses SA, Sukumar D. Bone metabolism in obesity and weight loss. Annu Rev Nutr. 2012;32:287\u2013309. https:\/\/doi.org\/10.1146\/annurev.nutr.012809.104655.","journal-title":"Annu Rev Nutr"},{"key":"2365_CR86","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/jcsm.12567","volume":"11","author":"B Kirk","year":"2020","unstructured":"Kirk B, Zanker J, Duque G. Osteosarcopenia: epidemiology, diagnosis, and treatment-facts and numbers. J Cachexia Sarcopenia Muscle. 2020;11:609\u201318. https:\/\/doi.org\/10.1002\/jcsm.12567.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2365_CR87","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/nrendo.2016.153","volume":"13","author":"N Napoli","year":"2017","unstructured":"Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL, et al. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13:208\u201319. https:\/\/doi.org\/10.1038\/nrendo.2016.153.","journal-title":"Nat Rev Endocrinol"},{"key":"2365_CR88","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1007\/s00198-025-07664-1","volume":"36","author":"L Karam","year":"2025","unstructured":"Karam L, Mabilleau G, Paccou J. Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity. Osteoporos Int. 2025;36:2115\u201326. https:\/\/doi.org\/10.1007\/s00198-025-07664-1.","journal-title":"Osteoporos Int"},{"key":"2365_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-025-09022-y","volume":"26","author":"YJ Alalwani","year":"2025","unstructured":"Alalwani YJ, Alshahrani AS, Alsudays AI, Almutairi RNA, Arab RAH, Alqahtani RSA, et al. Differential effects of GLP-1 receptor agonists on diabetic osteopathy in type 2 diabetes: a patient-stratified network meta-analysis. BMC Musculoskelet Disord. 2025;26:742. https:\/\/doi.org\/10.1186\/s12891-025-09022-y.","journal-title":"BMC Musculoskelet Disord"},{"key":"2365_CR90","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00592-025-02468-5","volume":"62","author":"Y Tan","year":"2025","unstructured":"Tan Y, Liu S, Tang Q. Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis. Acta Diabetol. 2025;62:589\u2013606. https:\/\/doi.org\/10.1007\/s00592-025-02468-5.","journal-title":"Acta Diabetol"},{"key":"2365_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-025-00483-4","volume":"13","author":"H Liu","year":"2025","unstructured":"Liu H, Li B, Liu L, Ying W, Rosen CJ. Weight loss induced bone loss: mechanism of action and clinical implications. Bone Res. 2025;13:99. https:\/\/doi.org\/10.1038\/s41413-025-00483-4.","journal-title":"Bone Res"},{"key":"2365_CR92","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2026.2640980","author":"AJ Scheen","year":"2026","unstructured":"Scheen AJ. GLP-1-derived therapies and risk of sarcopenia: myth or reality? Expert Opin Drug Saf. 2026. https:\/\/doi.org\/10.1080\/14740338.2026.2640980.","journal-title":"Expert Opin Drug Saf"},{"key":"2365_CR93","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","volume":"24","author":"DJ Drucker","year":"2025","unstructured":"Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025;24:631\u201350. https:\/\/doi.org\/10.1038\/s41573-025-01183-8.","journal-title":"Nat Rev Drug Discov"},{"key":"2365_CR94","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2025.1165","author":"A Maihemuti","year":"2025","unstructured":"Maihemuti A, Cui C, Wang Q, Amuti R, Chau WW, Chai S, et al. Glucagon like peptide-1 receptor agonists for sarcopenia and muscle wasting disorders: a systematic review of efficacy and mechanisms. Aging Dis. 2025. https:\/\/doi.org\/10.14336\/AD.2025.1165.","journal-title":"Aging Dis"},{"key":"2365_CR95","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1210\/js.2017-00446","volume":"2","author":"AWK Tan","year":"2018","unstructured":"Tan AWK, Subaran SC, Sauder MA, Chai W, Jahn LA, Fowler DE, et al. GLP-1 and insulin recruit muscle microvasculature and dilate conduit artery individually but not additively in healthy humans. J Endocr Soc. 2018;2:190\u2013206. https:\/\/doi.org\/10.1210\/js.2017-00446.","journal-title":"J Endocr Soc"},{"key":"2365_CR96","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16\u201331. https:\/\/doi.org\/10.1093\/ageing\/afy169.","journal-title":"Age Ageing"},{"key":"2365_CR97","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/acr.23608","volume":"70","author":"SP Messier","year":"2018","unstructured":"Messier SP, Resnik AE, Beavers DP, Mihalko SL, Miller GD, Nicklas BJ, et al. Intentional weight loss in overweight and obese patients with knee osteoarthritis: is more better? Arthritis Care Res (Hoboken). 2018;70:1569\u201375. https:\/\/doi.org\/10.1002\/acr.23608.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2365_CR98","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt0548","volume":"388","author":"Y Yang","year":"2025","unstructured":"Yang Y, Hao C, Jiao T, Yang Z, Li H, Zhang Y, et al. Osteoarthritis treatment via the GLP-1-mediated gut-joint axis targets intestinal FXR signaling. Science. 2025;388:eadt0548. https:\/\/doi.org\/10.1126\/science.adt0548.","journal-title":"Science"},{"key":"2365_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05323-7","author":"C Meurot","year":"2022","unstructured":"Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R, et al. Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep. 2022. https:\/\/doi.org\/10.1038\/s41598-022-05323-7.","journal-title":"Sci Rep"},{"key":"2365_CR100","unstructured":"Meurot C, Martin C, Vieubled M, Toillon I, Deldycke C, Cheron V, Trombetta S, Sibran W, Rattenbach R, Berenbaum F. Intra-articular liraglutide halts osteoarthritis progression, surpassing dexamethasone in synovial and cartilage protection. Arthritis Rheumatol. 2025;77."},{"key":"2365_CR101","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.arth.2024.06.008","volume":"39","author":"MS Lavu","year":"2024","unstructured":"Lavu MS, Porto JR, Hecht CJ 2nd, Kaelber DC, Sculco PK, Heckmann ND, et al. The five-year incidence of progression to osteoarthritis and total joint arthroplasty in patients prescribed glucagon-like peptide 1 receptor agonists. J Arthroplasty. 2024;39:2433-2439 e2431. https:\/\/doi.org\/10.1016\/j.arth.2024.06.008.","journal-title":"J Arthroplasty"},{"key":"2365_CR102","doi-asserted-by":"publisher","first-page":"232596712412971","DOI":"10.1177\/23259671241297157","volume":"13","author":"JR Porto","year":"2025","unstructured":"Porto JR, Lavu MS, Hecht CJ 2nd, Kaelber DC, Sculco PK, Heckmann ND, et al. The impact of contemporary glucagon-like peptide-1 receptor agonists on the onset, severity, and conversion to arthroplasty in hip and knee osteoarthritis. Orthop J Sports Med. 2025;13:23259671241297156. https:\/\/doi.org\/10.1177\/23259671241297157.","journal-title":"Orthop J Sports Med"},{"key":"2365_CR103","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae165","author":"S Borchers","year":"2025","unstructured":"Borchers S, Skibicka KP. GLP-1 and its analogs: does sex matter? Endocrinology. 2025. https:\/\/doi.org\/10.1210\/endocr\/bqae165.","journal-title":"Endocrinology"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02365-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02365-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02365-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:05:24Z","timestamp":1790366724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02365-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":103,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2365"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02365-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.S-R. reports personal speaker fees from Nutricia outside the submitted work. J-Y.R. is President of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), a not-for-profit organisation receiving Unrestricted Educational Grands from corporate partners. J-Y.R. is an Editorial Board member of Drugs. J-Y.R. was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Other authors did not report any conflicts of interest in relation to this work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors alone are responsible for the views expressed in this article, and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated.","order":2,"name":"Ethics","label":"Disclaimer","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All materials related to this work are freely available on the Open Science Framework deposit \u2013","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All materials related to this work are freely available on the Open Science Framework deposit \u2013","order":7,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J-Y.R. and J.A.T. are at the initiative of the research question. C.B. and Y.M. are the main investigators of the present research. C.B. drafted the protocol, which was reviewed by A.S. and J-Y.R. C.B. developed the search strategies and identified potential references for inclusion in the project. Y.M. C.B. and D.S.R. screened the references and selected the relevant ones. Conflicts were resolved by C.B. and Y.M. Y.M. performed the manual literature search. Y.M., C.B. and D.S.R., S.v.H. extracted the data, and performed the risk of bias assessment. Meta-analyses models were run by Y.M and C.B. The results were first interpreted by C.B., J-Y.R., A.S. and then by the rest of the experts, including A.M., R.R., and G.D. The first draft of the manuscript was written by C.B. All authors reviewed and approved the final manuscript.","order":8,"name":"Ethics","label":"Authors\u2019 Contribution","group":{"name":"EthicsHeading","label":"Declarations"}}]}}